Isavuconazonium

Summary

Isavuconazonium (CHEMBL1183349) is an approved small-molecule prodrug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 2
• Chemistry: 717.8 Da · C35H35F2N8O5S+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1183349
Name	Isavuconazonium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6918606
ChEBI	CHEBI:85978
Molecular formula	C35H35F2N8O5S+
Molecular weight	717.8
InChIKey	RSWOJTICKMKTER-QXLBVTBOSA-N

SMILES: C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=O)CNC)(C5=C(C=CC(=C5)F)F)O

IUPAC name: [2-[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazol-4-ium-4-yl]ethoxycarbonyl-methylamino]-3-pyridinyl]methyl 2-(methylamino)acetate

ChEBI definition: An organic cation that is the cationic portion of isavuconazonium sulfate (a prodrug for isavuconazole, an antifungal agent used for the treatment of invasive aspergillosis and invasive mucormycosis).

Pharmacological roles (ChEBI): prodrug, ergosterol biosynthesis inhibitor, EC 1.14.13.70 (sterol 14α-demethylase) inhibitor, antifungal agent.

Also known as: Bal-8557, BAL-8557000, BAL8557, Isavuconazonium, Isavuconazonium cation, Isavuconazonium ion, ISAVUCONAZONIUM, C0088427

Parent form; salt/anhydrous children: CHEMBL291921, CHEMBL1688829, CHEMBL3137333

Patent coverage: 121 distinct patent families (231 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 230 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03241550	PHASE1	COMPLETED	A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
NCT04096157	PHASE1	COMPLETED	A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).